How to Get Leqvio (Inclisiran) in Louisiana

What Is Leqvio and Why Is It Prescribed?

Leqvio is a small interfering RNA (siRNA) therapy that targets PCSK9 messenger RNA inside liver cells, reducing LDL-C by roughly 50% with only two injections per year after a loading phase. The FDA approved inclisiran on December 22, 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy [1].

The ORION-10 trial (N=1,561) and ORION-11 trial (N=1,617) together demonstrated that inclisiran 300 mg reduced LDL-C by 52.3% and 49.9% respectively at day 510, compared with placebo (P<0.0001 for both), with a safety profile comparable to placebo [2]. Because cardiovascular disease remains the leading cause of death in Louisiana, where age-adjusted heart disease mortality runs above the national average according to CDC data [3], access to effective LDL-lowering agents carries real clinical weight.

According to the American College of Cardiology/American Heart Association 2022 Guideline on the Management of Blood Cholesterol, PCSK9 inhibitors and PCSK9 siRNA therapies are indicated as add-on therapy when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe [4]. Clinicians at HealthRX follow this framework when evaluating Louisiana patients for Leqvio eligibility.

Who Qualifies for Leqvio in Louisiana?

Qualification rests on two criteria: a confirmed diagnosis and an uncontrolled LDL-C level despite current therapy. The FDA-approved indications are HeFH and established ASCVD as an adjunct to diet and maximally tolerated statin therapy [1]. Most commercial insurers and Medicare Part D plans mirror these indications in their coverage criteria.

Established ASCVD includes prior myocardial infarction, prior stroke, symptomatic peripheral arterial disease, or coronary revascularization. HeFH is typically confirmed by clinical criteria (Simon Broome or Dutch Lipid Clinic Network scoring) or, where available, genetic testing showing a pathogenic LDL-receptor, ApoB, or PCSK9 variant [5].

Patients with LDL-C below 70 mg/dL on current therapy are unlikely to receive prior authorization approval from most Louisiana commercial plans. A fasting LDL-C at or above 70 mg/dL, documented on at least one recent lipid panel taken while the patient is on maximally tolerated statin therapy, is the minimum threshold most plans require [6].

Labs Required Before Starting Leqvio in Louisiana

Before a Louisiana provider submits a Leqvio prescription or prior authorization, the following laboratory workup is standard:

Lipid panel. A fasting or non-fasting comprehensive lipid panel measuring total cholesterol, LDL-C (direct or calculated), HDL-C, and triglycerides is required. Most payers want a result dated within 90 days of the authorization request. The ORION trials used direct LDL-C measurement in participants with triglycerides above 400 mg/dL [2].

Hepatic function. Because inclisiran is administered as a subcutaneous injection processed by the liver, baseline ALT and AST are recommended. The prescribing information notes that no dose adjustment is required for mild-to-moderate hepatic impairment, but severe hepatic impairment has not been studied [1].

Renal function. No dose adjustment is needed for renal impairment, including patients on hemodialysis, based on pharmacokinetic data from the inclisiran label [1]. A baseline creatinine or eGFR is still useful for overall cardiovascular risk documentation.

Statin documentation. Prior authorization reviewers want to see current statin therapy, the dose, and evidence that the dose is maximally tolerated or that statins were trialed and not tolerated. A note documenting statin intolerance with at least one prior statin attempt at two different doses satisfies most Louisiana commercial-plan criteria [6].

The ACC/AHA cholesterol guideline recommends a fasting lipid panel 4 to 12 weeks after initiating or changing lipid-lowering therapy and every 3 to 12 months thereafter to assess adherence and response [4].

How to Get a Leqvio Prescription in Louisiana: Step by Step

Getting a Leqvio prescription in Louisiana follows a predictable sequence regardless of whether you see a provider in person or via telehealth.

Step 1. Establish a qualifying diagnosis. Your provider must document HeFH or established ASCVD in the medical record. If you have a prior genetic test or cardiology report, bring it to the appointment.

Step 2. Confirm labs. Schedule a fasting lipid panel if your most recent result is older than 90 days. Order ALT, AST, and creatinine at the same draw.

Step 3. See a licensed Louisiana provider. Any MD, DO, NP, or PA licensed in Louisiana may prescribe Leqvio, as discussed in the prescriber-eligibility section below. Telehealth is a fully legal option for this prescription in Louisiana [7].

Step 4. Submit prior authorization. Your provider or their staff submits a PA request to your insurer using the criteria above. Medicare Part D plans follow CMS coverage guidance. Commercial plans use their own formulary criteria, many of which align with the 2022 ACC/AHA guideline [4].

Step 5. Obtain the medication. Leqvio is a specialty drug. Most plans require dispensing through a specialty pharmacy. Novartis operates the Leqvio Co-Pay Assistance Program, which may reduce out-of-pocket costs for eligible commercially insured patients [1].

Step 6. Receive the injection. Leqvio is administered subcutaneously by a healthcare provider in a clinical setting. Patients cannot self-inject. The injection schedule is: one dose on day 1, a second dose on day 90, then one dose every 6 months [1].

Telehealth Leqvio Prescribing in Louisiana

Telehealth prescribing is legal in Louisiana for inclisiran. Louisiana RS 37:1271 and the Louisiana Board of Medical Examiners telemedicine standards permit licensed Louisiana physicians, NPs, and PAs to prescribe Schedule-exempt medications via synchronous audio-video telehealth visits, provided a valid patient-provider relationship exists [7].

A telehealth provider cannot administer the injection remotely. After issuing the prescription, the telehealth clinician sends it to a specialty pharmacy and coordinates with a local Louisiana infusion clinic, cardiologist office, or primary care office that will perform the actual subcutaneous injection. This two-step model is the standard workflow for Leqvio telehealth patients in Louisiana.

When selecting a telehealth platform, confirm that the prescribing clinician holds an active Louisiana medical license and that the platform complies with the Louisiana Board of Medical Examiners 2023 telemedicine rules, which require a documented patient history and a clinically appropriate physical-exam equivalent for new-patient prescriptions [7].

Who Can Prescribe Leqvio in Louisiana?

Any of the following licensed Louisiana practitioners may legally prescribe inclisiran:

MDs and DOs. Full prescriptive authority. No collaborative practice agreement required.

Nurse Practitioners (NPs). Louisiana NPs with full practice authority (granted after January 1, 2023, under Louisiana RS 37:913 amendments) may prescribe independently. NPs without full practice authority must operate under a collaborative practice agreement with a supervising physician [8].

Physician Assistants (PAs). Louisiana PAs may prescribe under a supervising physician's authority, consistent with their delegation agreement on file with the Louisiana State Board of Medical Examiners [8].

Cardiologists, lipidologists, and endocrinologists are the most common specialists prescribing Leqvio in Louisiana, but primary care providers are fully eligible and increasingly manage PCSK9-pathway therapies as the drug class matures. The American Association of Clinical Endocrinology 2022 consensus statement on dyslipidemia management supports primary care initiation of PCSK9 inhibitor or siRNA therapy in qualified patients [9].

Prior Authorization in Louisiana: What Documentation Is Required?

Prior authorization is required by virtually every commercial insurer and Medicare Part D plan in Louisiana that covers Leqvio at all. Louisiana Medicaid does not currently cover inclisiran, so Medicaid patients must explore patient-assistance programs.

The standard PA package for Louisiana commercial plans typically includes:

• Chart note documenting HeFH (by clinical or genetic criteria) or established ASCVD
• LDL-C lab result (dated within 90 days) showing LDL at or above 70 mg/dL for ASCVD, or at or above 100 mg/dL for HeFH-only indications on some plans
• Current statin name, dose, and duration of therapy
• Documentation of maximally tolerated statin dose or statin intolerance (two-statin rule)
• Evidence that ezetimibe was trialed (some plans waive this if LDL is severely elevated)
• Letter of medical necessity from the prescribing provider

The 2022 ACC/AHA Guideline on Cholesterol states: "In patients with very high-risk ASCVD who require additional LDL-C lowering, a PCSK9 inhibitor is recommended (Class I, LOE A) if LDL-C remains 70 mg/dL or higher after maximally tolerated statin and ezetimibe therapy" [4]. Using this specific guideline language in a letter of medical necessity strengthens PA submissions for Louisiana commercial plans.

Medicare Part D plans must follow CMS guidance. As of the 2023 CMS plan year, CMS does not mandate coverage of inclisiran, and individual Part D plans set their own formulary tiers, meaning PA criteria vary plan by plan. The formulary look-up tool at medicare.gov allows Louisiana patients to check their specific plan's inclisiran tier before initiating the PA process.

Appeals are available if a PA is denied. Louisiana law (RS 22:1821) requires insurers to issue PA decisions within 3 business days for standard requests and 1 business day for expedited requests. Denied requests may be appealed internally and, if upheld, referred to the Louisiana Department of Insurance for external review.

503A Pharmacy Options for Inclisiran in Louisiana

503A pharmacies are traditional compounding pharmacies regulated by state boards of pharmacy. A Louisiana-licensed 503A pharmacy may legally compound inclisiran formulations for individual patients if a valid prescription exists and the compounding is done pursuant to that prescription for a specific patient. However, several important cautions apply.

FDA-approved inclisiran (Leqvio) is manufactured under strict GMP conditions and validated for subcutaneous injection. Compounded inclisiran is not FDA-approved, meaning potency, sterility, and purity cannot be guaranteed to the same standard. The FDA's guidance on compounded drugs under Section 503A of the Food, Drug, and Cosmetic Act notes that pharmacies may compound copies of commercially available drugs only when a patient has a documented clinical difference justifying the compounding, such as an allergy to an excipient [10].

Most Louisiana specialty pharmacies with a cardiovascular formulary carry brand-name Leqvio through specialty distribution channels and do not need to compound. Patients interested in 503A compounded inclisiran should discuss the regulatory and quality distinctions with their prescribing provider before proceeding. The Louisiana Board of Pharmacy maintains a current list of licensed in-state 503A pharmacies [11].

How Long Until You Receive Leqvio in Louisiana?

The total timeline from first telehealth or in-person visit to first injection typically spans 2 to 6 weeks for commercially insured Louisiana patients. Breaking that down:

• Provider visit and labs: 1 to 7 days (labs may be same-day at a national chain or 2 to 3 days for results)
• PA submission and decision: 3 to 10 business days (Louisiana law requires a maximum of 3 business days for standard PA decisions)
• Specialty pharmacy dispensing and shipping: 3 to 7 business days
• Scheduling the injection appointment at a clinical site: 1 to 14 days depending on local availability

Patients experiencing a PA denial add at least 5 to 15 business days for an internal appeal. An expedited PA, available for patients with documented clinical urgency, must be decided within 1 business day under Louisiana RS 22:1821.

The ORION-10 trial measured LDL-C reduction from baseline to day 510, showing a time-averaged LDL-C reduction of 52.3% for patients who completed the loading and maintenance dosing schedule [2]. Patients who delay treatment beyond the 90-day loading window or miss a scheduled every-6-month dose lose a portion of that sustained reduction, so minimizing administrative delays matters clinically.

Transferring an Existing Leqvio Prescription to Louisiana

Patients relocating to Louisiana who already have an active Leqvio prescription in another state can transfer the prescription to a Louisiana specialty pharmacy, provided the original prescribing provider is licensed in Louisiana or a new Louisiana provider writes a fresh prescription.

Leqvio prescriptions are not controlled substances, so interstate transfer involves no DEA-schedule restriction. The receiving specialty pharmacy in Louisiana will request medical records documenting the diagnosis, recent LDL-C labs, and current dosing history. Most Louisiana commercial plans require the Louisiana prescriber to submit a new PA, since PA authorizations are plan-specific and do not transfer with the patient.

Patients transferring mid-course (for example, after receiving their day-1 and day-90 doses in another state) should schedule their next dose to maintain the every-6-month schedule. The inclisiran prescribing information states that if a dose is missed by less than 3 months, it should be given and the next dose scheduled 6 months from that date. If the dose is missed by more than 3 months, restart with the loading sequence [1].

Cost and Patient Assistance for Louisiana Residents

Leqvio carries a list price above $3,500 per dose as of 2024, making financial assistance programs a practical necessity for most patients.

Novartis Leqvio Co-Pay Assistance Program. Commercially insured patients in Louisiana may be eligible for co-pay assistance through Novartis that reduces their out-of-pocket expense to as low as $0 per dose, subject to program eligibility requirements. Program terms are available at novartis.com and through the specialty pharmacy dispensing the drug.

Louisiana Medicaid. Inclisiran is not on the Louisiana Medicaid preferred drug list as of mid-2025, so Medicaid beneficiaries must either seek a non-preferred exception (unlikely to succeed without extensive documentation) or explore alternative LDL-lowering therapies covered by Medicaid, such as rosuvastatin or atorvastatin.

Medicare Part D. Coverage varies by plan. Patients with low incomes may qualify for the Low Income Subsidy (Extra Help program), which reduces Part D cost-sharing. The Medicare Extra Help income threshold for 2025 is 150% of the federal poverty level.

Patient Assistance Program (PAP). Novartis offers a PAP for uninsured or underinsured patients. Applications are processed through the specialty pharmacy or the prescribing provider's office.

Alternative PCSK9-pathway therapies with broader Louisiana Medicaid or commercial formulary coverage include evolocumab (Repatha) and alirocumab (Praluent), both monoclonal antibodies requiring biweekly or monthly self-injection. The 2022 ACC/AHA guideline notes that the choice between PCSK9 monoclonal antibodies and inclisiran may be driven by patient preference, injection frequency, and formulary access rather than differential efficacy [4].

Monitoring After Starting Leqvio in Louisiana

After the first inclisiran injection, a follow-up lipid panel at 60 to 90 days confirms response. The ORION-10 data show that LDL-C reduction reaches near-maximum at day 90, the time of the second loading dose [2]. If LDL-C is not adequately controlled after two loading doses, the prescriber should reassess adherence to concurrent statin therapy and diet before escalating further.

The American Association of Clinical Endocrinology 2022 dyslipidemia consensus recommends annual LDL-C monitoring for patients on stable PCSK9-targeted therapy once the target LDL-C is achieved [9]. For very-high-risk ASCVD patients, that LDL-C target is below 55 mg/dL according to AACE 2022 guidelines [9].

Injection-site reactions are the most common adverse effect reported with inclisiran, occurring in 2.6% of inclisiran-treated patients vs. 0.9% of placebo patients in the pooled ORION-10 and ORION-11 populations [2]. These reactions are generally mild and transient. No clinically significant drug interactions have been identified, as inclisiran is not metabolized by CYP450 enzymes [1].